2024
Testosterone Recovery and Associated Impact on Patient-Reported Health-Related Quality of Life (HRQoL) after Treatment with 6 Months of GnRH Agonist with or without Abiraterone Acetate plus Prednisone (AAP) and Apalutamide (Apa) in the FORMULA-509 Trial
Moningi S, Nguyen P, Rathkopf D, Zurita-Saavedra A, Spratt D, Dess R, Liauw S, Szmulewitz R, Einstein D, Bubley G, Yu J, An Y, Wong A, Feng F, Mckay R, Rose B, Shin K, Taplin M, Kollmeier M, Hoffman K. Testosterone Recovery and Associated Impact on Patient-Reported Health-Related Quality of Life (HRQoL) after Treatment with 6 Months of GnRH Agonist with or without Abiraterone Acetate plus Prednisone (AAP) and Apalutamide (Apa) in the FORMULA-509 Trial. International Journal Of Radiation Oncology • Biology • Physics 2024, 120: e563-e564. DOI: 10.1016/j.ijrobp.2024.07.1247.Peer-Reviewed Original ResearchMonths of GnRH agonistTestosterone recoveryGnRH agonistAssociated with lackClinically meaningful changeBaseline testosteroneAssociated with testosterone recoveryMedian follow-upEvaluated prior to treatmentTreatment groupsTrial randomized patientsHormonal functionPatient-reported health-related quality of lifeLog-rank testCompletion of treatmentMultivariate logistic regressionWilcoxon rank-sumPatient-reported HRQoL.Salvage radiationGleason scoreAbiraterone acetateHigher PSARecovery 1 yearRandomized patientsHealth-related quality of lifeLong-Term Patient-Reported Health-Related Quality of Life in the Randomized FORMULA-509 Trial of Salvage Radiotherapy and 6 Months of GnRH Agonist with Either Bicalutamide or Abiraterone Acetate Plus Prednisone and Apalutamide after Radical Prostatectomy
Hoffman K, Nguyen P, Rathkopf D, Zurita-Saavedra A, Spratt D, Dess R, Liauw S, Szmulewitz R, Einstein D, Bubley G, Yu J, An Y, Wong A, Feng F, Mckay R, Rose B, Lee K, Kibel A, Taplin M, Kollmeier M. Long-Term Patient-Reported Health-Related Quality of Life in the Randomized FORMULA-509 Trial of Salvage Radiotherapy and 6 Months of GnRH Agonist with Either Bicalutamide or Abiraterone Acetate Plus Prednisone and Apalutamide after Radical Prostatectomy. International Journal Of Radiation Oncology • Biology • Physics 2024, 120: s54. DOI: 10.1016/j.ijrobp.2024.07.088.Peer-Reviewed Original ResearchAbiraterone acetate plus prednisoneMonths of GnRH agonistAcetate plus prednisonePatient-reported health-related quality of lifeEPIC-26Hormonal functionHealth-related quality of lifeGnRH agonistTreatment armsTreatment to 1 yearQuality of lifeMental statusMetastasis-free survivalBaseline to endCompletion of treatmentSalvage radiationSalvage radiotherapyOncological outcomesRadical prostatectomyClinically meaningful differencesSaint Louis University Mental Status ExamNear baselineClinically meaningful declineT-scoreHormonal domainsCancer care and the coconut tree: all in which it lives, and has come before
Yu J. Cancer care and the coconut tree: all in which it lives, and has come before. JNCI Cancer Spectrum 2024, 8: pkae083. PMID: 39428118, PMCID: PMC11491160, DOI: 10.1093/jncics/pkae083.Peer-Reviewed Original ResearchReply to O. Saifi et al
Yu J, DeStephano D, Horowitz D, Gross C, Cheng S. Reply to O. Saifi et al. Journal Of Clinical Oncology 2024, 42: 3763-3764. PMID: 39079081, DOI: 10.1200/jco-24-01228.Peer-Reviewed Original ResearchThe IDH paradox: Meta-analysis of alkylating chemotherapy in IDH-wild type and -mutant lower grade gliomas
Kinslow C, Roy S, Iwamoto F, Brown P, DeStephano D, Canoll P, Qureshi S, Gallito M, Sisti M, Bruce J, Horowitz D, Kachnic L, Neugut A, Yu J, Mehta M, Cheng S, Wang T. The IDH paradox: Meta-analysis of alkylating chemotherapy in IDH-wild type and -mutant lower grade gliomas. Neuro-Oncology 2024, 26: 1839-1849. PMID: 38943513, PMCID: PMC11449043, DOI: 10.1093/neuonc/noae102.Peer-Reviewed Original ResearchProgression-free survivalIDH-mutant gliomasLow grade gliomasOverall survivalIDH-wtAlkylating chemotherapyGrade gliomasChemotherapy improves overall survivalMeta-analysis of randomized clinical trialsEffects of alkylating chemotherapyCompared to radiotherapyIDH-mutant tumorsWorld Health OrganizationIDH-wt glioblastomaIDH-wt gliomasMeta-analysisDiagnosis of glioblastomaIDH-wt tumorsIDH-wild typeRandomized clinical trialsRandom-effects modelMagnitude of benefitGlioblastoma trialsAnaplastic morphologyOS benefitUpdated Analysis of Comparative Toxicity of Proton and Photon Radiation for Prostate Cancer
Yu J, DeStephano D, Jeffers B, Horowitz D, Soulos P, Gross C, Cheng S. Updated Analysis of Comparative Toxicity of Proton and Photon Radiation for Prostate Cancer. Journal Of Clinical Oncology 2024, 42: 1943-1952. PMID: 38507655, DOI: 10.1200/jco.23.01604.Peer-Reviewed Original ResearchIntensity-modulated radiation therapyProton beam therapyGU toxicityProstate cancerGI toxicityBenefits of proton beam therapyIntensity-modulated radiation therapy patientsPBT patientsLocalized prostate cancerTreatment-related toxicityComparison of GIStatistically significant differenceRadiation therapyBeam therapySEER-MedicareToxicity of protonProcedure codesComparative effectiveness studiesObservational studyPatientsSignificant differenceCancerMonthsComparing GIProstatePatient-reported health-related quality of life (HRQoL) in the randomized FORMULA-509 trial of salvage radiotherapy and 6 months of GnRH agonist with either bicalutamide or abiraterone acetate plus prednisone (AAP) and apalutamide (Apa) after radical prostatectomy (RP).
Hoffman K, Nguyen P, Rathkopf D, Zurita A, Spratt D, Dess R, Liauw S, Szmulewitz R, Einstein D, Bubley G, Yu J, An Y, Wong A, Feng F, McKay R, Rose B, Shin K, Kibel A, Taplin M, Kollmeier M. Patient-reported health-related quality of life (HRQoL) in the randomized FORMULA-509 trial of salvage radiotherapy and 6 months of GnRH agonist with either bicalutamide or abiraterone acetate plus prednisone (AAP) and apalutamide (Apa) after radical prostatectomy (RP). Journal Of Clinical Oncology 2024, 42: 260-260. DOI: 10.1200/jco.2024.42.4_suppl.260.Peer-Reviewed Original ResearchAbiraterone acetate plus prednisoneSaint Louis University Mental Status ExamMonths of GnRH agonistPatient-reported health-related quality of lifeEPIC-26Radical prostatectomyHealth-related quality of lifeGnRH agonistTreatment armsHormonal functionPROMIS FatigueTreatment to 1 yearQuality of lifeAcetate plus prednisoneMental statusMetastasis-free survivalBaseline to endMental status examStandardized T scoresMild neurocognitive disorderCompletion of treatmentSalvage radiationSalvage radiotherapyOncological outcomesClinically meaningful differencesIntensification of ADT with enzalutamide in high-risk patients with biochemical relapse following radical prostatectomy undergoing salvage radiation: Initial results from RTOG 3506 (STEEL).
Posadas E, Gay H, Rodgers J, Morgan T, Xiao Y, Yu J, Michalski J, Bouchard M, Desai N, Funk R, Boike T, Jurgens D, Wong A, Shen X, Miyawaki L, Bland C, Hairston J, Sandler H, Pugh S, Feng F. Intensification of ADT with enzalutamide in high-risk patients with biochemical relapse following radical prostatectomy undergoing salvage radiation: Initial results from RTOG 3506 (STEEL). Journal Of Clinical Oncology 2024, 42: 131-131. DOI: 10.1200/jco.2024.42.4_suppl.131.Peer-Reviewed Original ResearchAndrogen deprivation therapyProgression free survivalSalvage radiotherapyHigh-risk featuresBiochemical relapseHigh-risk patientsRadical prostatectomyLHRH analogsDecreased lymphocytesAndrogen receptorMonths of androgen deprivation therapyGrade 3 adverse eventsProgression free survival benefitStandard androgen deprivation therapyMedian follow-up timeGrade 4 AEsPara-aortic radiotherapyProstate cancer patientsEnzalutamide armGleason 9Salvage radiationDeprivation therapyNodal involvementFree survivalRT boostBuilding on the past and creating a brave future: a message from the incoming editor in chief
Yu J. Building on the past and creating a brave future: a message from the incoming editor in chief. JNCI Cancer Spectrum 2024, 8: pkad096. PMID: 38185809, PMCID: PMC10868384, DOI: 10.1093/jncics/pkad096.Peer-Reviewed Original Research
2023
MGMT promoter methylation in 1p19q-intact gliomas
Kinslow C, Siegelin M, Iwamoto F, Gallitto M, Neugut A, Yu J, Cheng S, Wang T. MGMT promoter methylation in 1p19q-intact gliomas. Journal Of Neuro-Oncology 2023, 166: 73-78. PMID: 38114801, DOI: 10.1007/s11060-023-04515-z.Peer-Reviewed Original ResearchConceptsNational Cancer DatabaseMGMT promoter methylationOverall survivalIDH-wildtypeMGMT statusAdjuvant temozolomideAnaplastic gliomasPromoter methylationAssociated with poor survivalAssociation of MGMTClinical efficacy of temozolomideIDH-mutant astrocytomasCox proportional hazards regression modelsIDH-wildtype gliomasKaplan-Meier methodWell-powered prospective studiesMGMT promoter statusEfficacy of temozolomideProportional hazards regression modelsInternational randomized phaseStandard-of-careHazards regression modelsCATNON trialAnaplastic astrocytomaCancer DatabasePrognosis and risk of suicide after cancer diagnosis
Kinslow C, Kumar P, Olfson M, Wall M, Petridis P, Horowitz D, Wang T, Kachnic L, Cheng S, Prigerson H, Yu J, Neugut A. Prognosis and risk of suicide after cancer diagnosis. Cancer 2023, 130: 588-596. PMID: 38018695, DOI: 10.1002/cncr.35118.Peer-Reviewed Original ResearchConceptsRisk of suicideCancer diagnosisSuicide riskCancer sitesMonths of diagnosisRelative risk of suicideSuicide deathsBaseline suicide riskSuicide ratesNewly diagnosed cancerYears of follow-upImpact of prognosisExistential distressAssociated with suicide riskMortality ratioWeighted linear regression modelImpending deathLinear regression modelsUS populationRelative riskGeneral populationBaseline riskAssociated with overall prognosisEnd Results databaseOverall survival rateSelected-Lesion SRS as a Novel Strategy in Treatment of Patients with Multiple Brain Metastases
Singh C, Theriault B, An Y, Yu J, Knisely J, Shepard M, Wegner R, Warnick R, Peker S, Samanci Y, Trifiletti D, Lee C, Yang H, Bernstein K, Kondziolka D, Tripathi M, Mathieu D, Mantziaris G, Pikis S, Sheehan J, Chiang V. Selected-Lesion SRS as a Novel Strategy in Treatment of Patients with Multiple Brain Metastases. International Journal Of Radiation Oncology • Biology • Physics 2023, 117: e150-e151. DOI: 10.1016/j.ijrobp.2023.06.971.Peer-Reviewed Original ResearchWhole-brain radiation therapyTreatment of patientsSystemic diseaseBrain metastasesLesion locationIntracranial lesionsPrior whole-brain radiation therapyMultiple brain metastasesBrain radiation therapyUntreated brain metastasesBrain metastasis treatmentCurrent practice patternsSigns/symptomsPresence of symptomsMATERIAL/METHODSImmunotherapy optionsSystemic therapyUntreated lesionsMedical oncologyPerilesional edemaDrug optionsClinical trialsPractice patternsClinical indicationsMetastasis treatmentFORMULA-509: A Multicenter Randomized Trial of Post-Operative Salvage Radiotherapy (SRT) and 6 Months of GnRH Agonist with Either Bicalutamide or Abiraterone Acetate/Prednisone (AAP) and Apalutamide (Apa) Post-Radical Prostatectomy (RP)
Nguyen P, Kollmeier M, Rathkopf D, Hoffman K, Zurita-Saavedra A, Spratt D, Dess R, Liauw S, Szmulewitz R, Einstein D, Bubley G, Yu J, An Y, Wong A, Feng F, Mckay R, Rose B, Shin K, Kibel A, Taplin M. FORMULA-509: A Multicenter Randomized Trial of Post-Operative Salvage Radiotherapy (SRT) and 6 Months of GnRH Agonist with Either Bicalutamide or Abiraterone Acetate/Prednisone (AAP) and Apalutamide (Apa) Post-Radical Prostatectomy (RP). International Journal Of Radiation Oncology • Biology • Physics 2023, 117: s81-s82. DOI: 10.1016/j.ijrobp.2023.06.401.Peer-Reviewed Original ResearchPSA progression-free survivalMetastasis-free survivalMonths of GnRH agonistAbiraterone acetate/prednisoneSalvage radiotherapyGnRH agonistPre-planned analysisPost-RPStratification factorsProgression-free survivalPost-radical prostatectomyMedian follow-upSubgroup of patientsMulticenter randomized trialOne-sided type I errorPre-planned subgroup analysisStatistically significant benefitTwo-sided p-valuePelvic nodesOpen-labelPrimary endpointSecondary endpointsInvestigator-initiatedSafety profileAdverse eventsMGMT Promoter Methylation Predicts Survival in 1p19q-Codeleted Gliomas after Chemotherapy
Kinslow C, Rae A, Kumar P, Grinband J, Gill B, McKhann G, Sisti M, Bruce J, Canoll P, Iwamoto F, Yu J, Kachnic L, Cheng S, Wang T. MGMT Promoter Methylation Predicts Survival in 1p19q-Codeleted Gliomas after Chemotherapy. International Journal Of Radiation Oncology • Biology • Physics 2023, 117: e117. DOI: 10.1016/j.ijrobp.2023.06.902.Peer-Reviewed Original ResearchMGMT promoter methylationMGMT promoter statusMGMT promoter methylation statusAssociated with poor survivalNational Cancer DatabaseOverall survivalUnmethylated MGMTPromoter methylation statusPromoter methylationPromoter statusAlkylating chemotherapyPoor survivalMultivariate Cox proportional hazards regression modelsResponse to alkylating chemotherapyProgression-free survivalCox proportional hazards regression modelsMethylation statusProportional hazards regression modelsReceipt of chemotherapyHazards regression modelsCourse of treatmentAnaplastic gliomasMGMT promoterCancer DatabaseDiagnosed gliomasSelected-Lesion Stereotactic Radiosurgery (SL-SRS) as a Novel Strategy in the Treatment of Patients With Multiple Brain Metastases
Theriault B, Singh C, Yu J, Knisely J, Shepard M, Wegner R, Warnick R, Peker S, Samanci Y, Trifiletti D, Lee C, Yang H, Bernstein K, Kondziolka D, Tripathi M, Mathieu D, Mantziaris G, Pikis S, Sheehan J, Chiang V. Selected-Lesion Stereotactic Radiosurgery (SL-SRS) as a Novel Strategy in the Treatment of Patients With Multiple Brain Metastases. Cureus 2023, 15: e45457. PMID: 37859877, PMCID: PMC10583225, DOI: 10.7759/cureus.45457.Peer-Reviewed Original ResearchWhole brain radiotherapyInternational Radiosurgery Research FoundationPrior whole brain radiotherapyBrain metastasesStereotactic radiosurgeryCommon reasonAsymptomatic brain metastasesNon-eloquent locationsSystemic treatment optionsMultiple brain metastasesPoor functional statusTreatment of patientsCentral nervous systemAttributable symptomsExtracranial diseaseSystemic therapyUntreated lesionsMedical oncologySystemic diseaseFunctional statusTreatment optionsClinical trialsSingle lesionLesion locationIntracranial lesionsMGMT Promoter Methylation Predicts Overall Survival after Chemotherapy for 1p/19q-Codeleted Gliomas.
Kinslow C, Rae A, Taparra K, Kumar P, Siegelin M, Grinband J, Gill B, McKhann G, Sisti M, Bruce J, Canoll P, Iwamoto F, Horowitz D, Kachnic L, Neugut A, Yu J, Cheng S, Wang T. MGMT Promoter Methylation Predicts Overall Survival after Chemotherapy for 1p/19q-Codeleted Gliomas. Clinical Cancer Research 2023, 29: 4399-4407. PMID: 37611077, PMCID: PMC10872921, DOI: 10.1158/1078-0432.ccr-23-1295.Peer-Reviewed Original ResearchConceptsAssociated with worse survivalOverall survivalMGMT promoter statusUnmethylated MGMTWorse survivalPrognostic of progression-free survivalPromoter statusMultivariate Cox proportional hazards regression modelsWorld Health Organization gradeProgression-free survivalNational Cancer DatabaseCox proportional hazards regression modelsMGMT promoter methylationProportional hazards regression modelsGuiding treatment decisionsHazards regression modelsCourse of treatmentPredictive of responseMultiagent chemotherapyMGMT promoterCancer DatabaseMMGMTAlkylating chemotherapyChemotherapyEligible patientsRisk of Squamous Cell Carcinoma of the Breast Following Postmastectomy Implant Reconstruction in Women With Breast Cancer and Carcinoma in Situ
Kinslow C, Yu J, DeStephano D, Kachnic L, Cheng S, Neugut A, Horowitz D. Risk of Squamous Cell Carcinoma of the Breast Following Postmastectomy Implant Reconstruction in Women With Breast Cancer and Carcinoma in Situ. JAMA Surgery 2023, 158: 769-771. PMID: 37074722, PMCID: PMC10116379, DOI: 10.1001/jamasurg.2023.0262.Peer-Reviewed Original ResearchAssociation of MGMT Promoter Methylation With Survival in Low-grade and Anaplastic Gliomas After Alkylating Chemotherapy
Kinslow C, Mercurio A, Kumar P, Rae A, Siegelin M, Grinband J, Taparra K, Upadhyayula P, McKhann G, Sisti M, Bruce J, Canoll P, Iwamoto F, Kachnic L, Yu J, Cheng S, Wang T. Association of MGMT Promoter Methylation With Survival in Low-grade and Anaplastic Gliomas After Alkylating Chemotherapy. JAMA Oncology 2023, 9: 919-927. PMID: 37200021, PMCID: PMC10196932, DOI: 10.1001/jamaoncol.2023.0990.Peer-Reviewed Original ResearchConceptsProgression-free survivalResponse to alkylating chemotherapyMGMT promoter methylationMGMT promoter statusOverall survivalAnaplastic gliomasIDH-mutantAlkylating chemotherapyLow-gradePromoter methylationChemotherapy responseAssociated with progression-free survivalCohort studyPromoter statusAssociated with chemotherapy responseMultivariate Cox proportional hazards regression modelsClinical trials of patientsO6-methylguanine-DNA methyltransferaseCox proportional hazards regression modelsIDH wild-typeTrial of patientsIDH wild-type gliomasProportional hazards regression modelsO6-methylguanine-DNAProspective cohort studyCrazy Busy: The Blurring of Personal and Professional Boundaries as a Diversity, Equity, and Inclusion Issue
Ponce S, Seldon C, Yanagihara T, Horowitz D, Yu J, Kachnic L, Katz L. Crazy Busy: The Blurring of Personal and Professional Boundaries as a Diversity, Equity, and Inclusion Issue. International Journal Of Radiation Oncology • Biology • Physics 2023, 116: 276-279. PMID: 37179088, DOI: 10.1016/j.ijrobp.2023.01.010.Peer-Reviewed Original ResearchPrognosis and risk of suicide after cancer diagnosis.
Kinslow C, Kumar P, Wall M, Prigerson H, Olfson M, Kachnic L, Horowitz D, Yu J, Cheng S, Neugut A. Prognosis and risk of suicide after cancer diagnosis. Journal Of Clinical Oncology 2023, 41: 6634-6634. DOI: 10.1200/jco.2023.41.16_suppl.6634.Peer-Reviewed Original ResearchRisk of suicideImpact of prognosisSuicide riskCancer sitesCancer diagnosisRelative risk of suicideBaseline riskNewly diagnosed cancerYears of follow-upRates of suicideMortality ratioU.S. cancersMonths of diagnosisWeighted linear regression modelLinear regression modelsPsychiatric referralRelative riskU.S. populationPersons ageTriage patientsSuicide ratesEnd ResultsBaseline rateIncreased surveillanceRegression models